Koers Adynxx, Inc. Other OTC
Aandelen
ADYX
US00784D1037
Biotechnologie & Medisch Onderzoek
Omzet 2017 | - | Omzet 2018 | - | Marktkapitalisatie | 5 4,62 |
---|---|---|---|---|---|
Nettowinst (verlies) 2017 | -11 mln. -10,16 mln. | Nettowinst (verlies) 2018 | -5 mln. -4,62 mln. | EV/omzet 2017 * | - |
Nettoliquiditeiten 2017 * | - 0 | Nettoliquiditeiten 2018 * | - 0 | EV/omzet 2018 * | - |
K/w-verhouding 2017 * |
-
| K/w-verhouding 2018 * |
-
| Werknemers | - |
Dividendrendement 2017 * |
-
| Dividendrendement 2018 * |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Julien Mamet
FOU | Founder | - | 01-10-07 |
Rick Orr
CEO | Chief Executive Officer | - | 01-12-10 |
Dina Gonzalez
DFI | Director of Finance/CFO | - | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eckard Weber
BRD | Director/Board Member | 73 | - |
Stanley Abel
BRD | Director/Board Member | - | 01-01-08 |
Dennis Podlesak
CHM | Chairman | 66 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+64,23% | 55,07 mld. | |
-2,31% | 41,79 mld. | |
+44,36% | 40,22 mld. | |
-8,29% | 28,17 mld. | |
+11,97% | 26,28 mld. | |
-21,16% | 18,93 mld. | |
+7,54% | 13,03 mld. | |
+27,17% | 12,26 mld. | |
+25,72% | 12,21 mld. |